2025 Q4 -tulosraportti
Vain PDF
56 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 200 | - | - | ||
| 10 000 | - | - | ||
| 1 000 | - | - | ||
| 1 568 | - | - | ||
| 4 433 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 t sittenI hope this stock crashes to the ground like a soaking wet cat, the company goes bankrupt and that we all lose everything we have in this stock! And after that, I hope it continues down BELOW zero so that everyone who owns shares in this gets DEBT! There, now it will surely go up😉
·46 min sittenI'm looking forward to yet another red day tomorrow🙂
·2 t sittenI assume many decided to sell their shares today to have money to buy up TR. The sell-off has driven the share price down. I hope that from tomorrow we will start to climb the mountain in small steps. This is just my personal opinion 🙂
·2 t sittenWe are getting closer and closer to my prediction of price 5.8. I have placed a large buy order there. Exciting if we go under 8 tomorrow and break the resistance, then the order might be triggered perhaps even the same day?
·29 min sittenMy friend alfur, I have most likely owned circio shares quite a lot longer than you, I have thousands and sell nothing before I get well paid.. All I'm saying is that it's wrong towards especially new shareholders not to inform that this is still high risk.....
·2 t sittenNO ONE HAS NOTICED THE SMARTEST THING: WHERE THE PARTNER CHOSE TO TEST. 🧠🧬 Everyone is talking about THAT a top-5 player is testing circVec. Almost no one is asking WHERE. The answer is CNS. The Central Nervous System. The Brain. And that's where this gets interesting. CNS gene therapy is the most difficult discipline in the entire field. To reach the nerve cells, you have to administer high AAV doses — and it is precisely high doses that trigger the feared toxicity: nerve cell damage in dorsal root ganglia, liver damage, inflammation. That is the wall that has stopped countless CNS programs. Think about what that means. The partner didn't point circVec at a simple, safe target. They pointed it at the place in the body where the dose problem is worst. You don't test a new technology against the field's hardest wall — with your own money — unless you actually believe it can tear that wall down. And that's exactly what circVec promises: the same effect at a fraction of the dose. Less vector. Less toxicity. Exactly where it matters most. The choice of CNS is not a detail. It's a signal. One of the world's largest pharmaceutical companies says, with its wallet: "we believe this technology solves the hardest problem we have." It's not hope. It's direction. We know what we own. ♟️🧱🍷
·27 min sittenYou've again done the groundwork correctly here Bennyz👍 If you mean which cell in the human body is most difficult to treat with gene therapy, there isn't one completely unambiguous answer, but many researchers will point to neurons (nerve cells in the brain and central nervous system) as among the most complex. The reasons include: * The blood-brain barrier makes it difficult to get gene therapy vectors into the brain. * Neurons are often very long-lived and divide little or not at all. * The brain consists of many different subtypes of neurons that have different functions. * Even small errors in gene expression can affect complex networks and lead to unpredictable effects. * It is difficult to reach enough of the correct cells without affecting other areas.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
56 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenI hope this stock crashes to the ground like a soaking wet cat, the company goes bankrupt and that we all lose everything we have in this stock! And after that, I hope it continues down BELOW zero so that everyone who owns shares in this gets DEBT! There, now it will surely go up😉·46 min sittenI'm looking forward to yet another red day tomorrow🙂
- ·2 t sittenI assume many decided to sell their shares today to have money to buy up TR. The sell-off has driven the share price down. I hope that from tomorrow we will start to climb the mountain in small steps. This is just my personal opinion 🙂
- ·2 t sittenWe are getting closer and closer to my prediction of price 5.8. I have placed a large buy order there. Exciting if we go under 8 tomorrow and break the resistance, then the order might be triggered perhaps even the same day?·29 min sittenMy friend alfur, I have most likely owned circio shares quite a lot longer than you, I have thousands and sell nothing before I get well paid.. All I'm saying is that it's wrong towards especially new shareholders not to inform that this is still high risk.....
- ·2 t sittenNO ONE HAS NOTICED THE SMARTEST THING: WHERE THE PARTNER CHOSE TO TEST. 🧠🧬 Everyone is talking about THAT a top-5 player is testing circVec. Almost no one is asking WHERE. The answer is CNS. The Central Nervous System. The Brain. And that's where this gets interesting. CNS gene therapy is the most difficult discipline in the entire field. To reach the nerve cells, you have to administer high AAV doses — and it is precisely high doses that trigger the feared toxicity: nerve cell damage in dorsal root ganglia, liver damage, inflammation. That is the wall that has stopped countless CNS programs. Think about what that means. The partner didn't point circVec at a simple, safe target. They pointed it at the place in the body where the dose problem is worst. You don't test a new technology against the field's hardest wall — with your own money — unless you actually believe it can tear that wall down. And that's exactly what circVec promises: the same effect at a fraction of the dose. Less vector. Less toxicity. Exactly where it matters most. The choice of CNS is not a detail. It's a signal. One of the world's largest pharmaceutical companies says, with its wallet: "we believe this technology solves the hardest problem we have." It's not hope. It's direction. We know what we own. ♟️🧱🍷·27 min sittenYou've again done the groundwork correctly here Bennyz👍 If you mean which cell in the human body is most difficult to treat with gene therapy, there isn't one completely unambiguous answer, but many researchers will point to neurons (nerve cells in the brain and central nervous system) as among the most complex. The reasons include: * The blood-brain barrier makes it difficult to get gene therapy vectors into the brain. * Neurons are often very long-lived and divide little or not at all. * The brain consists of many different subtypes of neurons that have different functions. * Even small errors in gene expression can affect complex networks and lead to unpredictable effects. * It is difficult to reach enough of the correct cells without affecting other areas.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 200 | - | - | ||
| 10 000 | - | - | ||
| 1 000 | - | - | ||
| 1 568 | - | - | ||
| 4 433 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
56 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenI hope this stock crashes to the ground like a soaking wet cat, the company goes bankrupt and that we all lose everything we have in this stock! And after that, I hope it continues down BELOW zero so that everyone who owns shares in this gets DEBT! There, now it will surely go up😉·46 min sittenI'm looking forward to yet another red day tomorrow🙂
- ·2 t sittenI assume many decided to sell their shares today to have money to buy up TR. The sell-off has driven the share price down. I hope that from tomorrow we will start to climb the mountain in small steps. This is just my personal opinion 🙂
- ·2 t sittenWe are getting closer and closer to my prediction of price 5.8. I have placed a large buy order there. Exciting if we go under 8 tomorrow and break the resistance, then the order might be triggered perhaps even the same day?·29 min sittenMy friend alfur, I have most likely owned circio shares quite a lot longer than you, I have thousands and sell nothing before I get well paid.. All I'm saying is that it's wrong towards especially new shareholders not to inform that this is still high risk.....
- ·2 t sittenNO ONE HAS NOTICED THE SMARTEST THING: WHERE THE PARTNER CHOSE TO TEST. 🧠🧬 Everyone is talking about THAT a top-5 player is testing circVec. Almost no one is asking WHERE. The answer is CNS. The Central Nervous System. The Brain. And that's where this gets interesting. CNS gene therapy is the most difficult discipline in the entire field. To reach the nerve cells, you have to administer high AAV doses — and it is precisely high doses that trigger the feared toxicity: nerve cell damage in dorsal root ganglia, liver damage, inflammation. That is the wall that has stopped countless CNS programs. Think about what that means. The partner didn't point circVec at a simple, safe target. They pointed it at the place in the body where the dose problem is worst. You don't test a new technology against the field's hardest wall — with your own money — unless you actually believe it can tear that wall down. And that's exactly what circVec promises: the same effect at a fraction of the dose. Less vector. Less toxicity. Exactly where it matters most. The choice of CNS is not a detail. It's a signal. One of the world's largest pharmaceutical companies says, with its wallet: "we believe this technology solves the hardest problem we have." It's not hope. It's direction. We know what we own. ♟️🧱🍷·27 min sittenYou've again done the groundwork correctly here Bennyz👍 If you mean which cell in the human body is most difficult to treat with gene therapy, there isn't one completely unambiguous answer, but many researchers will point to neurons (nerve cells in the brain and central nervous system) as among the most complex. The reasons include: * The blood-brain barrier makes it difficult to get gene therapy vectors into the brain. * Neurons are often very long-lived and divide little or not at all. * The brain consists of many different subtypes of neurons that have different functions. * Even small errors in gene expression can affect complex networks and lead to unpredictable effects. * It is difficult to reach enough of the correct cells without affecting other areas.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 200 | - | - | ||
| 10 000 | - | - | ||
| 1 000 | - | - | ||
| 1 568 | - | - | ||
| 4 433 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt